---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-359185"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2026-08-20T20:06:14+00:00"
generated_at: "2026-08-20T20:07:13.198710+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Werewolf sells pre-clinical INDUCER and INDUKINE platforms to EMD Serono for $28M upfront plus $5M

## Summary
- Closed Aug 14, 2026 asset sale to EMD Serono: $28M upfront plus $5M upon transfer completion.
- Sale covers pre-clinical INDUCER and INDUKINE platforms; excludes WTX-124 and WTX-330 clinical programs.
- Company retains rights to advance WTX-124 and WTX-330; EMD grants exclusive license to related patents.
- License agreement enables sublicenses to Harpoon and Jazz under existing agreements; 24-month non-compete.

## SEC filing metadata
- accession: 0001193125-26-359185
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2026-08-20T20:06:14+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312526359185/0001193125-26-359185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312526359185/d141219d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-359185
- JSON: https://secwatch.observer/filing/0001193125-26-359185.json
- Plain text: https://secwatch.observer/filing/0001193125-26-359185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.